Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.

RenJi Hospital30 enrolled

Overview

Ciprofol is a new anesthetic, which combines with γ- Aminobutyric acid-a (GABAA) receptor. Ciprofol has shown equivalent anesthetic efficacy of propofol at 1/4 to 1/5 of the dosage. Ciprofol has the pharmacodynamic characteristics of rapid onset, stable and rapid recovery. Phase III clinical results showed that the incidence of injection pain and respiratory and circulatory depression of ciprofol was lower than that of propofol. Therefore, ciprofol has a good application prospect in sedation for gastrointestinal endoscopy, especially for obese patients. In the current study, we would explore the proper dose of Ciprofol in sedated gastrointestinal endoscopy in obese patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastric Cancer Gastric Ulcer Intestinal Polyps Intestinal Cancer

Interventions

ciprofolDRUG

The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age, ≤18 and ≤60 years, no gender limit 2. Undergoing routine gastrointestinal endoscopic diagnosis and treatment 3. American Society of Anesthesiologists (ASA) classification I-II 4. Body Mass Index(BMI) ≥28kg/m\^2 5. Clearly understand and voluntarily participate in the study; provide signed informed consent Exclusion Criteria: 1. Unhealthy alcohol drinking, defined by more than three standard drinks per day (≈10 g alcohol , equivalent to 50 g of strong Chinese spirits) 2. Drug abuse history within 3 months before the screening period 3. People who are known to be allergic to eggs, bean products, opioids and other drugs, propofol, etc 4. The researcher believes that patients should not participate in this trial

Outcomes

Primary Outcomes

Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.

Time frame: Patients will be followed for the duration of hospital stay, an expected average of 2 hours

Secondary Outcomes

Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.